Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Lung Cancer

Volumn 93, Issue , 2016, Pages 95-103

  Pérol, Maurice ^a   Ciuleanu, Tudor Eliade ^b   Arrieta, Oscar ^c   Prabhash, Kumar ^d   Syrigos, Konstantinos N ^e   Goksel, Tuncay ^f   Park, Keunchil ^g   Kowalyszyn, Ruben Dario ^h   Pikiel, Joanna ⁱ   Lewanski, Conrad R ^j   Thomas, Michael ^k   Dakhil, Shaker ^l   Kim, Joo Hang ^m   Karaseva, Nina ⁿ   Yurasov, Sergey ^o   Zimmermann, Annamaria ^o,p   Lee, Pablo ^p   Carter, Gebra Cuyun ^o,p   Reck, Martin ^p   Cappuzzo, Federico ^q   Garon, Edward B ^r   more..

^a CENTRE LÉON BÉRARD   (France)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d TATA MEMORIAL HOSPITAL   (India)

^e SOTIRIA GENERAL HOSPITAL   (Greece)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g Samsung Medical Center   (South Korea)

^h Centro de Investigaciones Clínicas   (Argentina)

ⁱ Poradnia Onkologiczna   (Poland)

^j CHARING CROSS HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l Cancer Center of Kansas   (United States)

^m Yonsei University College of Medicine   (South Korea)

ⁿ City Clinical Oncology Dispensary   (Russian Federation)

^o ELI LILLY AND COMPANY   (United States)

^p GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^q ISTITUTO TOSCANO TUMORI   (Italy)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Advanced metastatic non small cell lung cancer; Average symptom burden index; Lung cancer symptom scale; Quality of life

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM; TAXOID;

ADULT; ADVANCED CANCER; ARTICLE; AVERAGE SYMPTOM BURDEN INDEX; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DISTRESS SYNDROME; DYSPNEA; FATIGUE; FOLLOW UP; FUNCTIONAL STATUS; HEMOPTYSIS; HUMAN; LOSS OF APPETITE; LUNG CANCER SYMPTOM SCALE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; TUMOR GROWTH; YOUNG ADULT; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEMALE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METASTASIS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETREATMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PLATINUM; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RETREATMENT; TAXOIDS; TREATMENT OUTCOME;

EID: 84959441334     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.007     Document Type: Article

References (15)

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136:E359-E386. 10.1002/ijc.29210.
2. Chien C.R., Yang S.T., Chen C.Y., Fang H.Y., Tu C.Y., Tseng G.C., et al. Impact of the new lung cancer staging system for a predominantly advanced-disease patient population. J. Thorac. Oncol. 2010, 5:340-343. 10.1097/JTO.0b013e3181c8137a.
3. Carrato A., Vergnenègre A., Thomas M., McBride K., Medina J., Cruciani G. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr. Med. Res. Opin. 2014, 30:447-461. 10.1185/03007995.2013.860372.
4. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83:584-594. 10.4065/83.5.584.
5. Tishelman C., Lövgren M., Broberger E., Hamberg K., Sprangers M.A. Are the most distressing concerns of patients with inoperable lung cancer adequately assessed? A mixed-methods analysis. J. Clin. Oncol. 2010, 28:1942-1949. 10.1200/JCO.2009.23.3403.
6. Akin S., Can G., Aydiner A., Ozdilli K., Durna Z. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur. J. Oncol. Nurs. 2010, 14:400-409. 10.1016/j.ejon.2010.01.003.
7. Koczywas M., Cristea M., Thomas J., McCarty C., Borneman T., Del Ferraro C., et al. Interdisciplinary palliative care intervention in metastatic non-small-cell lung cancer. Clin. Lung Cancer 2013, 14:736-744. 10.1016/j.cllc.2013.06.008.
8. Bottomley A., Efficace F., Thomas R., Vanvoorden V., Ahmedzai S.H. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J. Clin. Oncol. 2003, 21:2982-2992. 10.1200/JCO.2003.01.203.
9. Cooley M.E. Symptoms in adults with lung cancer. A systematic research review. J. Pain Symptom Manage. 2000, 19:137-153. 10.1016/S0885-3924(99)00150-5.
10. Tishelman C., Degner L.F., Rudman A., Bertilsson K., Bond R., Broberger E., et al. Symptoms in patients with lung carcinoma: distinguishing distress from intensity. Cancer 2005, 104:2013-2021. 10.1002/cncr.21398.
11. Iyer S., Roughley A., Rider A., Taylor-Stokes G. The symptom burden of non-small cell lung cancer in USA: a real-world cross-sectional study. Support Care Cancer 2014, 22:181-187. 10.1007/s00520-013-1959-4.
12. Iyer S., Taylor-Stokes G., Roughley A. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany. Lung Cancer 2013, 81:288-293. 10.1016/j.lungcan.2013.03.008.
13. Ganquli A., Wiegand P., Gao X., Carter J.A., Botteman M.F., Ray S. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Qual. Life Res 2013, 22:1015-1026. 10.1007/s11136-012-0229-0.
14. Garon E.B., Ciuleanu T.E., Arrieta O., Prabhash K., Syrigos K.N., Goksel T., et al. Ramucirumab plus docetaxel versus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384:665-673. 10.1016/S0140-6736(14)60845-X.
15. Hollen P.J., Gralla R.J., Kris M.G., Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1994, 2:213-222. 10.1007/BF00365725.